These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25144777)

  • 41. Hepatobiliary manifestations of inflammatory bowel disease.
    Raj V; Lichtenstein DR
    Gastroenterol Clin North Am; 1999 Jun; 28(2):491-513. PubMed ID: 10372279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sclerosing cholangitis with granulocytic epithelial lesion: a benign form of sclerosing cholangiopathy.
    Zen Y; Grammatikopoulos T; Heneghan MA; Vergani D; Mieli-Vergani G; Portmann BC
    Am J Surg Pathol; 2012 Oct; 36(10):1555-61. PubMed ID: 22982898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colitis-associated sclerosing cholangitis in children: a single centre experience.
    Noble-Jamieson G; Heuschkel RB; Torrente F; Hadzic N; Zilbauer M
    J Crohns Colitis; 2013 Nov; 7(10):e414-8. PubMed ID: 23485432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and management of overlap syndromes.
    Bunchorntavakul C; Reddy KR
    Clin Liver Dis; 2015 Feb; 19(1):81-97. PubMed ID: 25454298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatic manifestations of inflammatory bowel diseases.
    Restellini S; Chazouillères O; Frossard JL
    Liver Int; 2017 Apr; 37(4):475-489. PubMed ID: 27712010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cystic fibrosis-associated liver disease.
    Herrmann U; Dockter G; Lammert F
    Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):585-92. PubMed ID: 20955961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of autoimmune and cholestatic liver disorders.
    Krok KL; Munoz SJ
    Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatobiliary associations with inflammatory bowel disease.
    Knight C; Murray KF
    Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):681-91. PubMed ID: 19929587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pancreatic Cystosis and Intrahepatic Biliopathy in a Young Adult with Cystic Fibrosis.
    Al Qatarneh S; Michel HK; Lindblad D; Ozolek J; Venkat V; Weiner DJ
    J Pediatr; 2018 Dec; 203():457-457.e1. PubMed ID: 30041939
    [No Abstract]   [Full Text] [Related]  

  • 51. Update on primary sclerosing cholangitis.
    Karlsen TH; Schrumpf E; Boberg KM
    Dig Liver Dis; 2010 Jun; 42(6):390-400. PubMed ID: 20172772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autoimmune hepatitis 2 years after the diagnosis of primary sclerosing cholangitis: an unusual overlap syndrome in a 17-year-old adolescent.
    Mueller T; Bianchi L; Menges M
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):232-6. PubMed ID: 18301306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of autoimmune hepatic diseases].
    Bueverov AO
    Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver and biliary problems in cystic fibrosis.
    Tanner MS
    J R Soc Med; 1992; 85 Suppl 19(Suppl 19):20-4. PubMed ID: 1597836
    [No Abstract]   [Full Text] [Related]  

  • 55. Primary sclerosing cholangitis: summary of a workshop.
    LaRusso NF; Shneider BL; Black D; Gores GJ; James SP; Doo E; Hoofnagle JH
    Hepatology; 2006 Sep; 44(3):746-64. PubMed ID: 16941705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hepatobiliary complications of idiopathic intestinal inflammations].
    Lukás M
    Cas Lek Cesk; 1997 Feb; 136(4):106-10. PubMed ID: 9221179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease.
    van de Peppel IP; Bertolini A; Jonker JW; Bodewes FAJA; Verkade HJ
    Curr Opin Pulm Med; 2017 Nov; 23(6):562-569. PubMed ID: 28837442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver complications in inflammatory bowel diseases.
    Wieser V; Gerner R; Moschen AR; Tilg H
    Dig Dis; 2013; 31(2):233-8. PubMed ID: 24030232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.
    Bastida G; Nos P; Aguas M; Beltrán B; Rubín A; Dasí F; Ponce J
    Aliment Pharmacol Ther; 2005 Nov; 22(9):775-82. PubMed ID: 16225485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.